Table 1.
Trial | Arm | n | mOS (95% CI) | Reference |
---|---|---|---|---|
ESPAC- 3(v2) | GEM | 537 | 23.6 (21.4–26.4) | 4 |
ESPAC-3(v2) | 5FU | 551 | 23.0 (21.1–25.0) | |
Pooled ESPAC-1/ESPAC-3(v1) | OBS | 225 | 16.8 (14.3–19.2) | 14 |
GEM gemcitabine, 5FU 5-fluorouracil with folinic acid, OBS observational arm, mOS median overall survival, 95% CI 95% confidence interval